These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

226 related articles for article (PubMed ID: 36518304)

  • 1. "Friends and foes" of multiple myeloma measurable/minimal residual disease evaluation by next generation flow.
    Pacelli P; Raspadori D; Bestoso E; Gozzetti A; Bocchia M
    Front Oncol; 2022; 12():1057713. PubMed ID: 36518304
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Eight-color multiparameter flow cytometry (EuroFlow-NGF) is as sensitive as next-generation sequencing in detecting minimal/measurable residual disease in autografts of patients with multiple myeloma.
    Urushihara R; Takezako N; Yoroidaka T; Yamashita T; Murata R; Satou K; Nakao S; Takamatsu H
    EJHaem; 2023 Feb; 4(1):184-191. PubMed ID: 36819171
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Minimal residual disease negativity by next-generation flow in non-CR myeloma patients.
    Kim SM; Yang NE; Jeong D; Yun J; Ryu S; Yoon SS; Ahn YO; Lee DS
    EJHaem; 2020 Nov; 1(2):563-566. PubMed ID: 35844993
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term CR Multiple Myeloma Patients Show Cured or MGUS-like Minimal Residual Disease Pattern by Next Generation Flow.
    Gozzetti A; Pacelli P; Raspadori D; Bestoso E; Tocci D; Sicuranza A; Bocchia M
    Rev Recent Clin Trials; 2022; 17(2):92-96. PubMed ID: 35578845
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical Utility of Next-Generation Flow-Based Minimal Residual Disease Assessment in Patients with Multiple Myeloma.
    Kim HY; Yoo IY; Lim DJ; Kim HJ; Kim SH; Yoon SE; Kim SJ; Cho D; Kim K
    Ann Lab Med; 2022 Sep; 42(5):558-565. PubMed ID: 35470273
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Next Generation Flow for highly sensitive and standardized detection of minimal residual disease in multiple myeloma.
    Flores-Montero J; Sanoja-Flores L; Paiva B; Puig N; García-Sánchez O; Böttcher S; van der Velden VHJ; Pérez-Morán JJ; Vidriales MB; García-Sanz R; Jimenez C; González M; Martínez-López J; Corral-Mateos A; Grigore GE; Fluxá R; Pontes R; Caetano J; Sedek L; Del Cañizo MC; Bladé J; Lahuerta JJ; Aguilar C; Bárez A; García-Mateo A; Labrador J; Leoz P; Aguilera-Sanz C; San-Miguel J; Mateos MV; Durie B; van Dongen JJM; Orfao A
    Leukemia; 2017 Oct; 31(10):2094-2103. PubMed ID: 28104919
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of next-generation sequencing (NGS) and next-generation flow (NGF) for minimal residual disease (MRD) assessment in multiple myeloma.
    Medina A; Puig N; Flores-Montero J; Jimenez C; Sarasquete ME; Garcia-Alvarez M; Prieto-Conde I; Chillon C; Alcoceba M; Gutierrez NC; Oriol A; Rosinol L; Bladè J; Gironella M; Hernandez MT; Gonzalez-Calle V; Cedena MT; Paiva B; San-Miguel JF; Lahuerta JJ; Mateos MV; Martinez-Lopez J; Orfao A; Gonzalez M; Garcia-Sanz R
    Blood Cancer J; 2020 Oct; 10(10):108. PubMed ID: 33127891
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Minimal Residual Disease in Multiple Myeloma: an Important Tool in Clinical Trials.
    Gozzetti A; Bocchia M
    Rev Recent Clin Trials; 2022; 17(1):9-10. PubMed ID: 34814822
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Minimal residual disease detection by next-generation sequencing in multiple myeloma: Promise and challenges for response-adapted therapy.
    Ferla V; Antonini E; Perini T; Farina F; Masottini S; Malato S; Marktel S; Lupo Stanghellini MT; Tresoldi C; Ciceri F; Marcatti M
    Front Oncol; 2022; 12():932852. PubMed ID: 36052251
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of next-generation sequencing versus next-generation flow cytometry for minimal-residual-disease detection in Chinese patients with multiple myeloma.
    Zhou M; Chen Y; Gong Y; Zhu M; Cen J; Pan J; Yan L; Shang J; Jin S; Shi X; Yao W; Yan S; Wu D; Chen S; Fu C; Yao L
    Discov Oncol; 2024 Mar; 15(1):78. PubMed ID: 38502423
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comprehensive characterization of circulating and bone marrow-derived multiple myeloma cells at minimal residual disease.
    Waldschmidt JM; Anand P; Knoechel B; Lohr JG
    Semin Hematol; 2018 Jan; 55(1):33-37. PubMed ID: 29759150
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Longitudinal minimal residual disease assessment in multiple myeloma patients in complete remission - results from the NMSG flow-MRD substudy within the EMN02/HO95 MM trial.
    Schmitz A; Brøndum RF; Johnsen HE; Mellqvist UH; Waage A; Gimsing P; Op Bruinink DH; van der Velden V; van der Holt B; Hansson M; Andersen NF; Frølund UC; Helleberg C; Schjesvold FH; Ahlberg L; Gulbrandsen N; Andreasson B; Lauri B; Haukas E; Bødker JS; Roug AS; Bøgsted M; Severinsen MT; Gregersen H; Abildgaard N; Sonneveld P; Dybkær K
    BMC Cancer; 2022 Feb; 22(1):147. PubMed ID: 35123422
    [TBL] [Abstract][Full Text] [Related]  

  • 13. MRD Assessment in Multiple Myeloma: Progress and Challenges.
    Bertamini L; D'Agostino M; Gay F
    Curr Hematol Malig Rep; 2021 Apr; 16(2):162-171. PubMed ID: 33950462
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Measurable Residual Disease Assessment Using Next-Generation Flow in Patients With Relapsed and Refractory Multiple Myeloma Treated With a Combination of Carfilzomib, Lenalidomide, and Dexamethasone.
    Yoroidaka T; Yamashita T; Murata R; Yoshihara K; Yoshihara S; Ueda M; Nakao S; Matsue K; Takamatsu H
    Anticancer Res; 2023 Jan; 43(1):157-165. PubMed ID: 36585165
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Minimal Residual Disease in Multiple Myeloma: State of the Art and Future Perspectives.
    Mina R; Oliva S; Boccadoro M
    J Clin Med; 2020 Jul; 9(7):. PubMed ID: 32645952
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Measurable Residual Disease by Next-Generation Flow Cytometry in Multiple Myeloma.
    Paiva B; Puig N; Cedena MT; Rosiñol L; Cordón L; Vidriales MB; Burgos L; Flores-Montero J; Sanoja-Flores L; Lopez-Anglada L; Maldonado R; de la Cruz J; Gutierrez NC; Calasanz MJ; Martin-Ramos ML; Garcia-Sanz R; Martinez-Lopez J; Oriol A; Blanchard MJ; Rios R; Martin J; Martinez-Martinez R; Sureda A; Hernandez MT; de la Rubia J; Krsnik I; Moraleda JM; Palomera L; Bargay J; Van Dongen JJM; Orfao A; Mateos MV; Blade J; San-Miguel JF; Lahuerta JJ;
    J Clin Oncol; 2020 Mar; 38(8):784-792. PubMed ID: 31770060
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical Applications and Future Directions of Minimal Residual Disease Testing in Multiple Myeloma.
    Oliva S; D'Agostino M; Boccadoro M; Larocca A
    Front Oncol; 2020; 10():1. PubMed ID: 32076595
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Minimal Residual Disease Assessment Within the Bone Marrow of Multiple Myeloma: A Review of Caveats, Clinical Significance and Future Perspectives.
    Romano A; Palumbo GA; Parrinello NL; Conticello C; Martello M; Terragna C
    Front Oncol; 2019; 9():699. PubMed ID: 31482061
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Interlaboratory Analytical Validation of a Next-Generation Sequencing Strategy for Clonotypic Assessment and Minimal Residual Disease Monitoring in Multiple Myeloma.
    Medina A; Jiménez C; Puig N; Sarasquete ME; Flores-Montero J; García-Álvarez M; Prieto-Conde I; Chillón C; Alcoceba M; González-Calle V; Gutiérrez NC; Jacobsen A; Vigil E; Hutt K; Huang Y; Orfao A; González M; Miller J; García-Sanz R
    Arch Pathol Lab Med; 2022 Jul; 146(7):862-871. PubMed ID: 34619755
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Minimal Residual Disease Assessment in Multiple Myeloma by Multiparametric Flow Cytometry.
    Rihova L; Vsianska P; Bezdekova R; Kralova R; Penka M; Krejci M; Pour L; Hájek R
    Klin Onkol; 2017; 30(Supplementum2):21-28. PubMed ID: 28903567
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.